Naoko Munakata was selected in the LSIPR 50 2018 publication for her influence on the life sciences industry. She featured in the government and policy section, as LSIPR reports.
Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.
Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.
Marie-Paule Kieny of the Drugs for Neglected Diseases Initiative is on a mission to remind stakeholders and governments that there is a moral imperative to pursue the fight against neglected diseases, as she tells LSIPR.
With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.
Thinking about how IP can assist a company long before it has fully developed is essential, says Leda Trivinos of Flagship Pioneering in an interview with LSIPR.
Anthony Atala combines the roles of surgeon and researcher in regenerative medicine, allowing him to stay mindful of why his work is important. He talks to LSIPR about his twin professions.
Mike Young was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
Now that Costa Rica has allowed adult stem cells to be used as part of regenerative therapies, the country should be able to attract more investment, say María del Pilar López and Esteban Monge of Zürcher Lawyers.
A handful of high-profile disputes over medical use patents have been decided in Japan, as Osamu Yamamoto of Yuasa and Hara reports.